1.
Dayan S, Ogilvie P, Rivkin AZ, Yoelin SG, Garcia JK, Ferrusi IL. OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study. J of Skin [Internet]. 2017Oct.27 [cited 2020Nov.25];1(3.1):s82. Available from: https://jofskin.org/index.php/skin/article/view/86